Boryung Valuation

Q: What is the Fair Price of A003850 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A003850 (₩10140) is trading above our estimate of [[fair value]] (₩2648.31)

Is A003850 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A003850 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A003850 (₩10140) is trading above our estimate of fair value (₩2648.31)

Significantly Below Fair Value: A003850 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A003850?

Key metric: As A003850 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A003850. This is calculated by dividing A003850's market cap by their current earnings.
What is A003850's PE Ratio?
PE Ratio	10.3x
Earnings	₩64.58b
Market Cap	₩667.88b

A003850 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.9x
Enterprise Value/EBITDA	7.3x
PEG Ratio	1x

Price to Earnings Ratio vs Peers

How does A003850's PE Ratio compare to its peers?

The above table shows the PE ratio for A003850 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	18.6x
A000640 Dong-A Socio Holdings	13.2x	n/a	₩674.5b
A086450 DongKook Pharmaceutical	14.1x	14.4%	₩767.7b
A001060 JW Pharmaceutical	16.7x	29.4%	₩591.4b
A214370 Caregen	30.5x	13.6%	₩1.1t
A003850 Boryung	10.3x	9.9%	₩667.9b

Price-To-Earnings vs Peers: A003850 is good value based on its Price-To-Earnings Ratio (10.3x) compared to the peer average (18.6x).

Price to Earnings Ratio vs Industry

How does A003850's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A007370 Jin Yang Pharmaceutical	2.4x	n/a	US$47.51m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A003850 is good value based on its Price-To-Earnings Ratio (10.3x) compared to the KR Pharmaceuticals industry average (15x).

Price to Earnings Ratio vs Fair Ratio

What is A003850's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A003850 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	10.3x
Fair PE Ratio	16.9x

Price-To-Earnings vs Fair Ratio: A003850 is good value based on its Price-To-Earnings Ratio (10.3x) compared to the estimated Fair Price-To-Earnings Ratio (16.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩513.9b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩19,910.00

-0.7%

-34.6%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

-4.8%

n/a

Medy-Tox

₩867.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩128,800.00

2.1%

-41.2%